Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
Status:
Terminated
Trial end date:
2017-07-19
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well everolimus works in treating patients with
pancreatic neuroendocrine tumors metastatic to the liver previously treated with surgery.
Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Giving everolimus after surgery may kill any tumors cells that remain.
Phase:
Phase 2
Details
Lead Sponsor:
Eastern Cooperative Oncology Group ECOG-ACRIN Cancer Research Group